Difference between revisions of "Stub"
Warner-admin (talk | contribs) m (Text replacement - "====Hormonotherapy====" to "====Endocrine therapy====") |
|||
Line 66: | Line 66: | ||
|} | |} | ||
===Regimen=== | ===Regimen=== | ||
− | ==== | + | ====Endocrine therapy==== |
*[[Abiraterone (Zytiga)]] | *[[Abiraterone (Zytiga)]] | ||
*[[Enzalutamide (Xtandi)]] | *[[Enzalutamide (Xtandi)]] | ||
Line 646: | Line 646: | ||
*[[Carmustine (BCNU)]] | *[[Carmustine (BCNU)]] | ||
*[[Cisplatin (Platinol)]] | *[[Cisplatin (Platinol)]] | ||
− | ==== | + | ====Endocrine therapy==== |
*[[Tamoxifen (Nolvadex)]] | *[[Tamoxifen (Nolvadex)]] | ||
Line 858: | Line 858: | ||
*[[Etoposide (Vepesid)]] | *[[Etoposide (Vepesid)]] | ||
*[[Cisplatin (Platinol)]] | *[[Cisplatin (Platinol)]] | ||
− | ==== | + | ====Endocrine therapy==== |
*[[Tamoxifen (Nolvadex)]] | *[[Tamoxifen (Nolvadex)]] | ||
====Radiotherapy==== | ====Radiotherapy==== | ||
Line 1,096: | Line 1,096: | ||
*[[Methotrexate (MTX)]] | *[[Methotrexate (MTX)]] | ||
*[[Fluorouracil (5-FU)]] | *[[Fluorouracil (5-FU)]] | ||
− | ==== | + | ====Endocrine therapy==== |
*[[Tamoxifen (Nolvadex)]] | *[[Tamoxifen (Nolvadex)]] | ||
Line 1,107: | Line 1,107: | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Mitoxantrone (Novantrone)]] | *[[Mitoxantrone (Novantrone)]] | ||
− | ==== | + | ====Endocrine therapy==== |
*[[Hydrocortisone (Cortef)]] | *[[Hydrocortisone (Cortef)]] | ||
Line 1,534: | Line 1,534: | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Vinorelbine (Navelbine)]] | *[[Vinorelbine (Navelbine)]] | ||
− | ==== | + | ====Endocrine therapy==== |
*[[Hydrocortisone (Cortef)]] | *[[Hydrocortisone (Cortef)]] | ||
Revision as of 00:42, 11 May 2021
Regimens that have not proven to be superior to a standard-of-care comparison and are thus unlikely to be expanded upon unless new evidence comes forward. This page is primarily to drive the Ontology.
3M
back to top |
3M: Mitomycin, Mitoxantrone, Methotrexate
Regimen
Chemotherapy
7+3i & Clofarabine
back to top |
7+3i & Clofarabine: 7 days of cytarabine, 3 days of idarubicin, Clofarabine
Regimen
Chemotherapy
7+3i & Lenalidomide
back to top |
7+3i & Lenalidomide: 7 days of cytarabine, 3 days of idarubicin, Lenalidomide
Regimen
Chemotherapy
Targeted therapy
7+4i
back to top |
7+4i: 7 days of cytarabine, 4 days of idarubicin
Regimen
Chemotherapy
7+5d
back to top |
7+5d: 7 days of cytarabine, 5 days of daunorubicin
Regimen
Chemotherapy
Abiraterone & Enzalutamide
back to top |
Regimen
Endocrine therapy
ACP
back to top |
ACP: Atezolizumab, Carboplatin, Paclitaxel
Regimen
Immunotherapy
Chemotherapy
Afatinib & Vinorelbine
back to top |
Regimen
Chemotherapy
Targeted therapy
A-ICE
back to top |
A-ICE: ATRA, Idarubicin, Cytarabine, Etoposide
Regimen
Chemotherapy
AME
back to top |
AME: Ara-C (Cytarabine), Mitoxantrone, Etoposide
Regimen
Chemotherapy
Amonafide & Cytarabine
back to top |
Regimen
Chemotherapy
Amsacrine & IDAC
back to top |
Amsacrine & IDAC: Amsacrine & Intermediate Dose Ara-C (Cytarabine)
Regimen
Chemotherapy
Bortezomib & Bevacizumab
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
White et al. 2012 (AMBER) | 2007-2009 | Randomized Phase II (E-esc) | Bortezomib | Did not meet primary endpoint of PFS (HR 0.74, 95% CI 0.43-1.28) |
Targeted therapy
Bortezomib & Siltuximab
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Orlowski et al. 2015 | 2006-2009 | Randomized Phase II (E-esc) | Bortezomib | Did not meet primary endpoint of PFS (HR 0.87, 95% CI 0.65-1.16) |
Targeted therapy
BTH (Taxotere)
back to top |
BTH: Bevacizumab, Taxotere (Docetaxel), Herceptin (Trastuzumab)
Regimen
Chemotherapy
Targeted therapy
BTOC
back to top |
BTOC: BCNU, Thiotepa, Oncovin (Vincristine), Cyclophosphamide
Regimen
Chemotherapy
CAD
back to top |
CAD: Cyclophosphamide, Adriamycin (Doxorubicin), DDP (Cisplatin)
Regimen
Chemotherapy
Capecitabine & Cisplatin (CX) & Bevacizumab
back to top |
Regimen
Chemotherapy
Targeted therapy
Capecitabine & Cisplatin (CX) & Ramucirumab
back to top |
Regimen
Chemotherapy
Targeted therapy
Capecitabine & Ruxolitinib
back to top |
Regimen
Chemotherapy
Targeted therapy
Capecitabine & Sorafenib
back to top |
Regimen
Chemotherapy
Targeted therapy
Capecitabine & Sunitinib
back to top |
Regimen
Chemotherapy
Targeted therapy
Capecitabine & Vinflunine
back to top |
Regimen
Chemotherapy
Capecitabine & Vinorelbine
back to top |
NX: Navelbine (Vinorelbine) & Xeloda (Capecitabine)
Regimen
Chemotherapy
Capecitabine, Cisplatin, Cetuximab, RT
back to top |
Regimen
Chemotherapy
Targeted therapy
Radiotherapy
- Concurrent radiation therapy
Capecitabine, Erlotinib, RT
back to top |
Regimen
Chemotherapy
Radiotherapy
- Concurrent radiation therapy
CarboMIP
back to top |
CarboMIP: Carboplatin, Mitomycin, Ifosfamide, Platinol (Cisplatin)
Regimen
Chemotherapy
Carboplatin & Epirubicin
back to top |
Regimen
Chemotherapy
Carboplatin & Paclitaxel (CP) & Bexarotene
back to top |
CP & Bexarotene: Carboplatin, Paclitaxel, Bexarotene
Regimen
Chemotherapy
Carboplatin & Paclitaxel (CP) & Cediranib
back to top |
CP & Cediranib: Carboplatin, Paclitaxel, Cediranib
Regimen
Chemotherapy
Targeted therapy
Carboplatin & Paclitaxel (CP) & Cetuximab
back to top |
CP & Cetuximab: Carboplatin, Paclitaxel, Cetuximab
Regimen
Chemotherapy
Targeted therapy
Carboplatin & Paclitaxel (CP) & Erlotinib
back to top |
CP & Erlotinib: Carboplatin, Paclitaxel, Erlotinib
Regimen
Chemotherapy
Targeted therapy
Carboplatin & Paclitaxel (CP) & PLD
back to top |
TC & PLD: Taxol (Paclitaxel), Carboplatin, Pegylated Liposomal Doxorubicin
Regimen
Chemotherapy
Carboplatin & Paclitaxel (CP) & Sorafenib
back to top |
CP & Sorafenib: Carboplatin, Paclitaxel, Sorafenib
Regimen
Chemotherapy
Targeted therapy
Carboplatin & Paclitaxel (CP) & Topotecan
back to top |
TC & Topotecan: Taxol (Paclitaxel), Carboplatin, Topotecan
Regimen
Chemotherapy
Carboplatin & Paclitaxel (CP) & Trebananib
back to top |
TC & Trebananib: Taxol (Paclitaxel), Carboplatin, Trebananib
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Vergote et al. 2019 (TRINOVA-3) | 2012-2014 | Phase III (E-esc) | TC | Did not meet primary endpoint of PFS (HR 0.93, 95% CI 0.79-1.09) |
Chemotherapy
Targeted therapy
Carboplatin & Paclitaxel (CP) & Veliparib
back to top |
CP & Veliparib: Carboplatin, Paclitaxel, Veliparib
Regimen
Chemotherapy
Targeted therapy
Carboplatin & Topotecan
back to top |
Regimen
Chemotherapy
CBM
back to top |
CBM: Capecitabine, Bevacizumab, Mitomycin
Regimen
Chemotherapy
Targeted therapy
CCG
back to top |
CCG: Cisplatin, Carboplatin, Gemcitabine
Regimen
Chemotherapy
Carboplatin & Etoposide (CE) & Ipilimumab
back to top |
CE & Ipilimumab: Carboplatin, Etoposide, Ipilimumab
Regimen
Chemotherapy
Immunotherapy
Carboplatin & Etoposide (CE) & Thalidomide
back to top |
CE & Thalidomide: Carboplatin, Etoposide, Thalidomide
Regimen
Chemotherapy
Targeted therapy
CIB
back to top |
CIB: Cisplatin, Ifosfamide, Bleomycin
Regimen
Chemotherapy
Cisplatin & Methotrexate
back to top |
Regimen
Chemotherapy
Cisplatin & Treosulfan
back to top |
Regimen
Chemotherapy
Cisplatin & Vincristine
back to top |
Regimen
Chemotherapy
Cisplatin, Avelumab, RT
back to top |
Regimen
Chemotherapy
Immunotherapy
Radiotherapy
- Concurrent radiation therapy
Cisplatin, Pemetrexed, RT
back to top |
Regimen
Chemotherapy
Radiotherapy
- Concurrent radiation therapy
CODE
back to top |
CODE: Cisplatin, Oncovin (Vincristine), Doxorubicin, Etoposide
Regimen
Chemotherapy
CYVADIC
back to top |
CYVADIC: CYclophosphamide, Vincristine, ADriamycin (Doxorubicin), Imidazole Carboxamide (Dacarbazine)
Regimen
Chemotherapy
DBCT
back to top |
DBCT: Dacarbazine, BCNU (Carmustine), Cisplatin, Tamoxifen
Regimen
Chemotherapy
Endocrine therapy
Docetaxel & Bavituximab
back to top |
Regimen
Chemotherapy
Targeted therapy
Docetaxel & Ganetespib
back to top |
Regimen
Chemotherapy
Targeted therapy
Docetaxel & Gefitinib
back to top |
Regimen
Chemotherapy
Targeted therapy
Docetaxel & Lapatinib
back to top |
Regimen
Chemotherapy
Targeted therapy
Docetaxel & Pertuzumab
back to top |
Regimen
Chemotherapy
Targeted therapy
Docetaxel & Selumetinib
back to top |
Regimen
Chemotherapy
Targeted therapy
Docetaxel & Sunitinib
back to top |
Regimen
Chemotherapy
Targeted therapy
Docetaxel & ziv-Aflibercept
back to top |
Regimen
Chemotherapy
Targeted therapy
Doxorubicin & Etoposide
back to top |
Regimen
Chemotherapy
Doxorubicin & Paclitaxel
back to top |
Regimen
Chemotherapy
Doxorubicin & Sorafenib
back to top |
Regimen
Chemotherapy
Targeted therapy
Doxorubicin & Streptozocin
back to top |
Regimen
Chemotherapy
Doxorubicin & Vinorelbine
back to top |
Regimen
Chemotherapy
EAP
back to top |
EAP: Etoposide, Adriamycin (Doxorubicin), Platinol (Cisplatin)
Regimen
Chemotherapy
ECVBP
back to top |
ECVBP: Epirubicin, Cyclophosphamide, Vindesine, Bleomycin, Prednisone
Regimen
Chemotherapy
- Epirubicin (Ellence)
- Cyclophosphamide (Cytoxan)
- Vindesine (Eldisine)
- Bleomycin (Blenoxane)
- Prednisone (Sterapred)
ELF
back to top |
ELF: Etoposide, Leucovorin, 5-FU
Regimen
Chemotherapy
Encorafenib monotherapy
back to top |
Regimen
Targeted therapy
EP & Ipilimumab
back to top |
EP & Ipilimumab: Etoposide, Platinol (Cisplatin), Ipilimumab
Regimen
Chemotherapy
Immunotherapy
EP, Tamoxifen, RT
back to top |
EP, GM-CSF, RT: Etoposide, Platinol (Cisplatin), Tamoxifen, Radiation Therapy
Regimen
Chemotherapy
Endocrine therapy
Radiotherapy
- Concurrent thoracic radiation therapy
Erlotinib & Figitumumab
back to top |
Regimen
Targeted therapy
Erlotinib & Onartuzumab
back to top |
Regimen
Targeted therapy
Erlotinib & Sunitinib
back to top |
Regimen
Targeted therapy
Erlotinib & Tivantinib
back to top |
Regimen
Targeted therapy
Everolimus & Vinorelbine
back to top |
Regimen
Chemotherapy
Targeted therapy
E-GEMOX
back to top |
E-GEMOX: Erlotinib, GEMcitabine, OXaliplatin
Regimen
Targeted therapy
Chemotherapy
FAP
back to top |
FAP: Fluorouracil, Alfa interferon, Platinol (Cisplatin)
Regimen
Chemotherapy
Immunotherapy
FEC & HP
back to top |
FEC & HP: Fluorouracil, Epirubicin, Cyclophosphamide, Herceptin (Trastuzumab), Pertuzumab
Regimen
Chemotherapy
Targeted therapy
FLA
back to top |
FLA: FLudarabine & Ara-C (Cytarabine)
Regimen
Chemotherapy
FLAI
back to top |
FLAI: FLudarabine, Ara-C (Cytarabine), Idarubicin
FIA: Fludarabine, Idarubicin, Ara-C (Cytarabine)
Regimen
Chemotherapy
FOLF-CB
back to top |
FOLF-CB: FOLinic acid, Fluorouracil, Cetuximab, Bevacizumab
Regimen
Chemotherapy
Targeted therapy
FULV & Trimetrexate
back to top |
FULV & Trimetrexate: 5-FU & LeucoVorin (Folinic acid), Trimetrexate
Regimen
Chemotherapy
Cisplatin & Gemcitabine (GC) & Veliparib
back to top |
GC & Veliparib: Gemcitabine, Cisplatin, Veliparib
Regimen
Chemotherapy
Targeted therapy
GVP
back to top |
GVP: Gemcitabine, Vinorelbine, Platinol (Cisplatin)
Regimen
Chemotherapy
Ibrutinib & Ublituximab
back to top |
Regimen
Targeted therapy
Ixabepilone & Bevacizumab
back to top |
Regimen
Chemotherapy
Targeted therapy
ME
back to top |
ME: Mitoxantrone & Etoposide
Regimen
Chemotherapy
MEV
back to top |
MEV: Mitomycin, Etoposide, Vindesine
Regimen
Chemotherapy
MFL
back to top |
MFL: Methyl-lomustine (MeCCNU), 5-FU, Leucovorin (Folinic acid)
Regimen
Chemotherapy
MFT
back to top |
MFL: Methotrexate, 5-FU, Tamoxifen
Regimen
Chemotherapy
Endocrine therapy
Mitoxantrone & Hydrocortisone
back to top |
Regimen
Chemotherapy
Endocrine therapy
MMF
back to top |
MMF: Methyl-lomustine (MeCCNU), Mitomycin, 5-FU
Regimen
Chemotherapy
MPP
back to top |
MPP: Melphalan, Prednisone, Procarbazine
Regimen
Chemotherapy
MTP
back to top |
MTP: Myocet (Non-pegylated liposomal doxorubicin), Trastuzumab, Paclitaxel
Regimen
Chemotherapy
Targeted therapy
MVC
back to top |
MVC: Mitomycin, Vindesine, Carboplatin
Regimen
Chemotherapy
NIP
back to top |
NIP: Navelbine (Vinorelbine), Ifosfamide, Platinol (Cisplatin)
Regimen
Chemotherapy
PD & Pembrolizumab
back to top |
PD & Pembrolizumab: Pomalidomide, Dexamethasone, Pembrolizumab
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Mateos et al. 2019 (KEYNOTE-183) | 2016-2017 | Phase III (E-esc) | PD | Seems to have inferior PFS (HR 1.53, 95% CI 1.05-2.22) |
Targeted therapy
Immunotherapy
PEI
back to top |
PEI: Platinol (Cisplatin), Etoposide, Ifosfamide
Regimen
Chemotherapy
PELF
back to top |
PELF: Platinol (Cisplatin), Epirubicin, Leucovorin, 5-FU
Regimen
Chemotherapy
PGT
back to top |
PGT: Platinol (Cisplatin), Gemcitabine, Taxol (Paclitaxel)
Regimen
Chemotherapy
PGV
back to top |
PGV: Platinol (Cisplatin), Gemcitabine, Vinorelbine
CGV: Cisplatin, Gemcitabine, Vinorelbine
Regimen
Chemotherapy
Pemetrexed & Cetuximab
back to top |
Regimen
Chemotherapy
Targeted therapy
Pemetrexed & Vandetanib
back to top |
Regimen
Chemotherapy
Targeted therapy
Pixantrone & Rituximab
back to top |
Regimen
Chemotherapy
Targeted therapy
PLD & Trebananib
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Marth et al. 2016 (TRINOVA-2) | 2011-2013 | Phase III (E-esc) | PLD | Did not meet primary endpoint of PFS (HR 0.92, 95% CI 0.68-1.24) |
Chemotherapy
Targeted therapy
PVI
back to top |
PVI: Platinol (Cisplatin), Vindesine, Ifosfamide
VIP: Vindesine, Ifosfamide, Platinol (Cisplatin)
Regimen
Chemotherapy
R-BEACOPP
R-BEACOPP: Rituximab, Bleomycin, Etoposide, Adriamycin (Doxorubicin), Cyclophosphamide, Oncovin (Vincristine), Procarbazine, Prednisone
Regimen
Targeted therapy
Chemotherapy
- Bleomycin (Blenoxane)
- Etoposide (Vepesid)
- Doxorubicin (Adriamycin)
- Cyclophosphamide (Cytoxan)
- Vincristine (Oncovin)
- Procarbazine (Matulane)
- Prednisone (Sterapred)
R-MegaCHOEP
back to top |
R-MegaCHOEP: Rituximab, high-dose (Mega) Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin), Oncovin (Vincristine), Etoposide, Prednisone
Targeted therapy
Chemotherapy
- Cyclophosphamide (Cytoxan)
- Doxorubicin (Adriamycin)
- Vincristine (Oncovin)
- Etoposide (Vepesid)
- Prednisone (Sterapred)
TCG
back to top |
TCG: Taxol (Paclitaxel), Carboplatin, Gemcitabine
Regimen
Chemotherapy
TCHL (Taxotere)
back to top |
TCHL: Taxotere (Docetaxel), Carboplatin, Herceptin (Trastuzumab), Lapatinib
Regimen
Chemotherapy
Targeted therapy
TCL (Taxotere)
back to top |
TCL: Taxotere (Docetaxel), Carboplatin, Lapatinib
Regimen
Chemotherapy
Targeted therapy
TEC
back to top |
TEC: Taxol (Paclitaxel), Epirubicin, Carboplatin
Regimen
Chemotherapy
TG+Bev
back to top |
TG+Bev: Taxotere (Docetaxel), Gemcitabine, Bevacizumab
Regimen
Chemotherapy
Targeted therapy
TH (Taxol) & Everolimus
back to top |
TH & Everolimus: Taxol (Paclitaxel), Herceptin (Trastuzumab), Everolimus
Regimen
Chemotherapy
Targeted therapy
TL (Taxotere)
back to top |
TL: Taxotere (Docetaxel) & Lapatinib
Regimen
Chemotherapy
Targeted therapy
TPCV
back to top |
TPCV: Thioguanine, Procarbazine, CCNU, Vincristine
Regimen
Chemotherapy
TX+Bev
back to top |
TX+Bev: Taxotere (Docetaxel), Xeloda (Capecitabine), Bevacizumab
Regimen
Chemotherapy
Targeted therapy
VADx
back to top |
VADx: Vincristine, Ara-C (Cytarabine), Dexamethasone
Regimen
Chemotherapy
VAPEC-B
back to top |
VAPEC-B: Vincristine, Adriamycin (Doxorubicin), Prednisolone, Etoposide, Cyclophosphamide, Bleomycin
Regimen
Chemotherapy
- Vincristine (Oncovin)
- Doxorubicin (Adriamycin)
- Prednisolone (Millipred)
- Etoposide (Vepesid)
- Cyclophosphamide (Cytoxan)
- Bleomycin (Blenoxane)
VBD
back to top |
VBD: Vinblastine, Bleomycin, DDP (Cisplatin)
Regimen
Chemotherapy
VBM (Vinblastine)
back to top |
VBM: Vinblastine, Bleomycin, Methotrexate
Regimen
Chemotherapy
VCE
back to top |
VCE: Vincristine, Carboplatin, Etoposide
Regimen
Chemotherapy
Vinorelbine & Hydrocortisone
back to top |
Regimen
Chemotherapy
Endocrine therapy
VNC
back to top |
VNC: Vincristine, Novantrone (Mitoxantrone), Cyclophosphamide
Regimen
Chemotherapy
VPV
back to top |
VPV: Vinblastine, Platinol (Cisplatin), VP-16 (Etoposide)
Regimen
Chemotherapy
VTDC
back to top |
VTDC: Velcade (Bortezomib), Thalidomide, Dexamethasone, Cyclophosphamide